February 12, 2018 / 2:08 PM / 7 days ago

BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The  Supplemental New Drug Application

Feb 12 (Reuters) - Adamis Pharmaceuticals Corp:

* ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE

* ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED

* ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED

* ADAMIS PHARMACEUTICALS CORP - FDA INDICATED IF NO MAJOR DEFICIENCIES IDENTIFIED, THEY ARE TARGETING SEPTEMBER 3, 2018 TO COMMUNICATE PROPOSED LABELING Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below